LYKA LABS
|
The Current P/E Ratio of LYKA LABS is -25.74.
| Share Price | ₹74.2 | Jul 01,2026 |
| Market Cap | ₹268.6 Cr | |
| Earnings-TTM | ₹-10.4 Cr | TTM-Consolidated Results |
| Price/Earnings | -25.74x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LYKA LABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹268.6 Cr] as on Jul 01,2026
(/) Earnings [ ₹-10.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -25.74x ]
Thus, for LYKA LABS , the investors are currently willing to pay -25.74 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LYKA LABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LYKA LABS over the last five years.
Historical PE (Price/Earnings) ratio chart of LYKA LABS
PE Ratio Performance Analysis for LYKA LABS
- LYKA LABS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 10.99x.
- LYKA LABS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LYKA LABS 's p/e ratio peaked in Mar2025 at 44.97x.
- LYKA LABS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does LYKA LABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LYKA LABS | -10.44 | -25.74 | 268.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 38.71 | 447,704.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 67.63 | 173,684.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 73.48 | 157,093.0 |
| CIPLA LTD | 3,869.79 | 30.41 | 117,699.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.98 | 111,792.0 |
| MANKIND PHARMA LTD | 1,926.41 | 53.39 | 102,844.0 |
| LUPIN LTD | 5,355.47 | 20.46 | 109,576.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.01 | 110,608.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 25.52 | 89,344.7 |
| LAURUS LABS LTD | 889.85 | 90.68 | 80,691.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LYKA LABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -25.74x |
| Max industry PE | 90.68x |
| Median industry PE | 30.41x |
| Average industry PE | 38.50x |
You may also like the below Video Courses